Tuesday, March 11, 2008

Fw: Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube.



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:58 PM
Subject: Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube.

[1]J Toxicol Sci. 2008 Feb; 33(1): 105-16
Takagi A, Hirose A, Nishimura T, Fukumori N, Ogata A, Ohashi N, Kitajima S, Kanno J

Nanomaterials of carbon origin tend to form various shapes of particles in micrometer dimensions. Among them, multi-wall carbon nanotubes (MWCNT) form fibrous or rod-shaped particles of length around 10 to 20 micrometers with an aspect ratio of more than three. Fibrous particles of this dimension including asbestos and some man-made fibers are reported to be carcinogenic, typically inducing mesothelioma. Here we report that MWCNT induces mesothelioma along with a positive control, crocidolite (blue asbestos), when administered intraperitoneally to p53 heterozygous mice that have been reported to be sensitive to asbestos. Our results point out the possibility that carbon-made fibrous or rod-shaped micrometer particles may share the carcinogenic mechanisms postulated for asbestos. To maintain sound activity of industrialization of nanomaterials, it would be prudent to implement strategies to keep good control of exposure to fibrous or rod-shaped carbon materials both in the workplace and in the future market until the biological/ carcinogenic properties, especially of their long-term biodurability, are fully assessed.



___
Source: http://www.hubmed.org/display.cgi?uids=18303189
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Never miss a thing. Make Yahoo your homepage.

Fw: [New diagnostic markers for malignant pleural mesothelioma.]



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:57 PM
Subject: [New diagnostic markers for malignant pleural mesothelioma.]

[1]Bull Cancer.. 2008 Feb 28; 95(2): 177-184
Grigoriu BD, Grégoire M, Chahine B, Scherpereel A

The increasing number of malignant pleural mesothelioma (MPM) is a serious public health problem. The prognosis of this tumor is poor and most of the patients are diagnosed late in the disease's course when curative treatment is no more an option. It is therefore necessary to diagnose earlier MPM in these patients in order to obtain a potential significant improvement in survival. Some serum markers have been previously proposed for MPM diagnosis but none had sufficient sensitivity and specificity for being use in routine. Recently, soluble mesothelin and osteopontin have been proposed as diagnostic markers for mesothelioma. The authors reviewed recent data concerning the utility of these two molecules in the diagnosis and the treatment of MPM. Mesothelin seems to be a specific marker for the epithelioid subtype of mesothelioma. Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis. However, there is not enough data yet to propose guidelines on the use of these markers in a day to day practice.



___
Source: http://www.hubmed.org/display.cgi?uids=18304902
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Never miss a thing. Make Yahoo your homepage.

Fwd: [A Case of Advanced Gastric Cancer Successfully Treated by Combination Therapy of S-1 and Docetaxel.]



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 5:02 AM
Subject: [A Case of Advanced Gastric Cancer Successfully Treated by Combination Therapy of S-1 and Docetaxel.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 287-290
Ikarashi S, Akiyama N, Motoyama H, Sasaki S, Ito H, Funakoshi K, Kato T, Arai F

A 70-year-old man with gastric cancer of Borrmann type 3, liver metastases and peritoneal dissemination was treated by combination therapy of S-1 and docetaxel (DOC). He received DOC intravenously at 40 mg/m(2) on day 1 and S-1 orally at 100 mg/body on day 1 to 14, repeated every 28 days. After 2 courses of treatment, a CT scan revealed improvement of the gastric wall thickness, the eminent decrease of the peritoneal fluid and the reduction of the liver metastasis. After 3 courses of treatment, the primary lesion was remarkably improved on endoscopic examination, and the tumor marker normalized after 4 courses of treatment. Toxicities included leukocytopenia (WHO grade 3), neutropenia ( grade 3), anorexia (grade 2), and nausea (grade 2). Outpatient chemotherapy was possible by reduction of dose (S-1 100--> 80 mg/body, DOC 40--> 32 mg/m2). The response was maintained on CT and endoscopic examination after 21 courses of treatment. A case of an advanced gastric cancer patient successfully treated by combination therapy of S-1 and DOC was reported.



___
Source: http://www.hubmed.org/display.cgi?uids=18281767
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer (The San Francisco Examiner)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer (The San Francisco Examiner)
To: mesothelioma77@gmail.com


WAYNE, N.J. and EMERYVILLE, Calif., Feb. 18 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the independent Data Monitoring Committee (DMC) concluded that the ...

Mon, 18 Feb 2008 16:20:33 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=14fcg4p3f/*http%3A//www.examiner.com/p-117014~Bayer_and_Onyx_Provide_Update_on_Phase_3_Trial_of_Nexavar_in_Patients_With_Non_Small_Cell_Lung_Cancer.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Bayer, Onyx Stop Nexavar Test on Lung-Cancer Patients (Update3) (Bloomberg.com)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Bayer, Onyx Stop Nexavar Test on Lung-Cancer Patients (Update3) (Bloomberg.com)
To: mesothelioma77@gmail.com


Feb. 18 (Bloomberg) -- Bayer AG, Germany's biggest drugmaker, and Onyx Pharmaceuticals Inc. stopped a study of the Nexavar cancer drug against lung tumors because the product failed to help patients live longer than standard treatment.

Mon, 18 Feb 2008 19:51:44 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=124knmprf/*http%3A//www.bloomberg.com/apps/news?pid=20601103&sid=aYskrh56aY10
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fw: Leading Asbestos-Cancer Group: CNN Expose Highlights Urgent Need for Medical Research



----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:22 PM
Subject: Leading Asbestos-Cancer Group: CNN Expose Highlights Urgent Need for Medical Research

CNN's recent expose on asbestos in children's toys demonstrates the shocking reality that the deadly carcinogen is virtually everywhere in our environment.

Fri, 29 Feb 2008 04:18:05 GMT

___
Source: http://watchmojo.com/health/blog/index.php/2008/02/29/leading-asbestos-cancer-group-cnn-expose-highlights-urgent-need-for-medical-research/
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 


Be a better friend, newshound, and know-it-all with Yahoo! Mobile. Try it now.

Fw: The 10 Most Frequently Asked Questions About Prostate Cancer



----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:22 PM
Subject: The 10 Most Frequently Asked Questions About Prostate Cancer

Submitted by MakemoneyToday on February 28, 2008 - 2:55pm. Cancer healthy illness mesothelioma Prostate Cancer Men by the time the reach the age of eighty and in all too many cases the problem will be that of ...

Thu, 28 Feb 2008 22:59:26 GMT

___
Source: http://bloggerparty.com/the_10_most_frequently_asked_questions_about_prostate_cancer
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 



Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fw: Lethal Asbestos Exposure - Mesothelioma cancer is fatal



----- Forwarded Message ----
From: blinkx SmartFeed: mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:21 PM
Subject: Lethal Asbestos Exposure - Mesothelioma cancer is fatal

Even secondary exposure to asbestos fibers can result in a terminal diagnosis of mesothelioma lung cancer. If you have symptoms of mesothelioma you need to seek a mesothelioma...

smartfeed@blinkx.com Thu, 28 Feb 2008 23:46:19 GMT

___
Source: http://www.blinkx.com/video/Revver/Lethal_Asbestos_Exposure_-_Mesothelioma_cancer_is_fatal~valRw7vYWSZ5EDuUxNirGLg&referrer=website_rss
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc 

 



Be a better friend, newshound, and know-it-all with Yahoo! Mobile. Try it now.

Fwd: Some Cancer Patients Turn to 'Coaches' (AP via Yahoo! Malaysia News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Feb 18, 2008 at 10:04 AM
Subject: Some Cancer Patients Turn to 'Coaches' (AP via Yahoo! Malaysia News)
To: mesothelioma77@gmail.com


The advice made her head spin: Have the lump removed. No, let them take the whole breast. Chemo? Radiation? Everyone seemed to have an opinion. "I just shut everyone down around me," said Bernie Brann, a newly diagnosed cancer patient from upstate New York. "You're just so overwhelmed with information." Bad advice, or just too much of it, can compound the trauma and damage done ...

Mon, 18 Feb 2008 10:51:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12eg6745c/*http%3A//malaysia.news.yahoo.com/ap/20080218/twl-cancer-coaches-1be00ca.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Nutritional and Prognostic Significance of Sick Euthyroid Syndrome in Non-small Cell Lung Cancer Patients.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Nutritional and Prognostic Significance of Sick Euthyroid Syndrome in Non-small Cell Lung Cancer Patients.
To: mesothelioma77@gmail.com


[1]Intern Med. 2008; 47(4): 211-216
Ekremcengiz S, Cetinkaya E, Altin S, Gunluoglu Z, Demir A, Gunluoglu G, Epozturk K

Objectives Our study aimed to determine the frequency of sick euthyroid syndrome (SES) among patients diagnosed as non-small cell lung cancer (NSCLC) and its association with the stage of the disease, Karnofsky index (KI), and nutritional parameters. Methods We enrolled 80 consecutive patients with newly diagnosed NSCLC. Cases with NSCLC were staged by using the TNM system. The cases were examined for thyroid function tests, KI and nutritional evaluation before treatment. Moreover, cases were investigated for their overall survival ratio. Results Out of 80 patients, SES was identified in 28 (35%). SES was more frequent among stage III (26%) and stage IV (62%) cases. The body mass index (BMI), KI and serum albumin level were found to be significantly low in cases with SES when compared to cases without SES. SES was found to be negatively correlated with BMI, KI and serum albumin level, and it was positively correlated with disease stage and weight loss. Additionally, the presence of SES was found as a prognostic factor at survival analysis (p=0.0002). Conclusion SES was frequently seen in cases with NSCLC. SES can be used as a predictor of poor prognosis in NSCLC patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18277019
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Proceedings of the 28th Annual Meeting of the Japanese Research Society for Surgical Cancer Immunology and the 29th Japanese Society for Loco-Regional Cancer Therapy]



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: [Proceedings of the 28th Annual Meeting of the Japanese Research Society for Surgical Cancer Immunology and the 29th Japanese Society for Loco-Regional Cancer Therapy]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2007 Nov; 34(12): 1899-2164






___
Source: http://www.hubmed.org/display.cgi?uids=18277397
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc